BR9811825A - Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue - Google Patents

Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue

Info

Publication number
BR9811825A
BR9811825A BR9811825-0A BR9811825A BR9811825A BR 9811825 A BR9811825 A BR 9811825A BR 9811825 A BR9811825 A BR 9811825A BR 9811825 A BR9811825 A BR 9811825A
Authority
BR
Brazil
Prior art keywords
level
blood
lactobacillus
fibrinogen
reduce
Prior art date
Application number
BR9811825-0A
Other languages
English (en)
Inventor
Hanna Bukowska
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of BR9811825A publication Critical patent/BR9811825A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/856—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Patente de Invenção: <B>"USO DE LACTOBACILLUS PARA REDUçãO DO NìVEL DE FIBRINOGêNIO NO SANGUE"<D>. A invenção refere-se ao uso de uma cepa de Lactobacillus para a fabricação de um medicamento para redução do nível de fribrinogênio e opcionalmente nível de colesterol, no sangue. O dito medicamento pode ser utilizado para profilaxia e/ou tratamento de doenças circulatórias.
BR9811825-0A 1997-08-05 1998-07-30 Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue BR9811825A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702860A SE510753C2 (sv) 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
PCT/SE1998/001423 WO1999007827A1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood

Publications (1)

Publication Number Publication Date
BR9811825A true BR9811825A (pt) 2000-08-15

Family

ID=20407874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811825-0A BR9811825A (pt) 1997-08-05 1998-07-30 Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue

Country Status (19)

Country Link
US (1) US6214336B1 (pt)
EP (1) EP0990024B1 (pt)
JP (1) JP4651814B2 (pt)
KR (1) KR100517755B1 (pt)
CN (1) CN1142995C (pt)
AR (1) AR016798A1 (pt)
AT (1) ATE326524T1 (pt)
AU (1) AU729413B2 (pt)
BR (1) BR9811825A (pt)
CA (1) CA2297023C (pt)
DE (1) DE69834560T2 (pt)
ES (1) ES2259457T3 (pt)
IL (1) IL134113A0 (pt)
NO (1) NO324881B1 (pt)
NZ (1) NZ502610A (pt)
PL (1) PL194697B1 (pt)
SE (1) SE510753C2 (pt)
WO (1) WO1999007827A1 (pt)
ZA (1) ZA986769B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830750B1 (en) 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
JP4193269B2 (ja) * 1999-03-04 2008-12-10 ビーエイチピーエイチ カンパニーリミテッド 新規な生体浄化活性型乳酸菌製剤
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
KR20030033950A (ko) * 2001-10-20 2003-05-01 주식회사 알엔에이 유산균 세포질 분획물 또는 유산균 파쇄물을 유효성분으로포함하는 동맥경화 억제제
FR2831395B1 (fr) * 2001-10-25 2004-06-11 Triballat Laiteries Procede de fabrication de produits fermentes a base de soja, produits fermentes obtenus par ce procede et ferments correspondants
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
CN1207382C (zh) * 2003-04-11 2005-06-22 上海光明乳业股份有限公司 植物乳杆菌st－iii菌株及其在调节血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
GB0424552D0 (en) * 2004-11-05 2004-12-08 Cambridge Theranostics Ltd Methods and means
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100909586B1 (ko) * 2007-06-01 2009-07-27 신현길 혈중 콜레스테롤 농도 저하에 효과적인 유산균 및 이들의혼합균주
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
JP5469873B2 (ja) * 2008-03-11 2014-04-16 株式会社日立製作所 回転電機
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
JP5140791B2 (ja) * 2008-11-27 2013-02-13 森下仁丹株式会社 乳酸菌含有血中ホモシステイン低減剤
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
DK3181134T3 (da) * 2009-06-19 2020-01-20 Dupont Nutrition Biosci Aps Bifidobakterier til behandling af diabetes og relaterede tilstande
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102031229B (zh) * 2009-09-24 2012-05-30 家医国际生化股份有限公司 具有肠胃道吸附能力及排除胆固醇能力的植物乳杆菌
CN102858948B (zh) * 2010-01-08 2015-11-25 热尔韦·达诺尼公司 具有抗氧化作用的乳酸杆菌
GB201319540D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201709763D0 (en) 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
CN110786435B (zh) * 2019-11-19 2022-08-23 四川农业大学 产高活性纤溶酶原激活剂的植物乳杆菌及用其发酵的果蔬汁饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0647551B2 (ja) * 1986-12-01 1994-06-22 株式会社ヤクルト本社 血圧降下剤
JP2676250B2 (ja) * 1989-03-20 1997-11-12 株式会社ヤクルト本社 血圧降下剤およびその製造法
JP2855290B2 (ja) * 1990-11-30 1999-02-10 株式会社ヤクルト本社 脂質代謝改善剤
JPH04264034A (ja) * 1991-02-18 1992-09-18 Snow Brand Milk Prod Co Ltd 生体内過酸化脂質抑制剤
JPH0525055A (ja) * 1991-07-22 1993-02-02 Yakult Honsha Co Ltd 血圧降下剤
SE469875C (sv) * 1991-07-25 1997-02-05 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
JPH06116155A (ja) * 1992-10-08 1994-04-26 Yakult Honsha Co Ltd 血清コレステロール低下剤
JP2801479B2 (ja) * 1992-10-09 1998-09-21 株式会社トクヤマ 補綴材料の製造方法
JP2992945B2 (ja) 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH08208512A (ja) * 1995-02-03 1996-08-13 Nippon Chem Res Kk 血栓形成阻害剤

Also Published As

Publication number Publication date
SE9702860L (sv) 1999-02-06
SE510753C2 (sv) 1999-06-21
SE9702860D0 (sv) 1997-08-05
NO20000268L (no) 2000-01-19
KR100517755B1 (ko) 2005-09-30
EP0990024B1 (en) 2006-05-17
CN1142995C (zh) 2004-03-24
AR016798A1 (es) 2001-08-01
DE69834560T2 (de) 2006-11-02
NZ502610A (en) 2000-12-22
NO20000268D0 (no) 2000-01-19
ZA986769B (en) 1999-02-02
US6214336B1 (en) 2001-04-10
PL194697B1 (pl) 2007-06-29
ES2259457T3 (es) 2006-10-01
PL338578A1 (en) 2000-11-06
CN1265141A (zh) 2000-08-30
JP2001512747A (ja) 2001-08-28
AU8372698A (en) 1999-03-01
WO1999007827A1 (en) 1999-02-18
CA2297023A1 (en) 1999-02-18
CA2297023C (en) 2010-03-30
AU729413B2 (en) 2001-02-01
EP0990024A1 (en) 2000-04-05
DE69834560D1 (de) 2006-06-22
KR20010022617A (ko) 2001-03-26
IL134113A0 (en) 2001-04-30
JP4651814B2 (ja) 2011-03-16
ATE326524T1 (de) 2006-06-15
NO324881B1 (no) 2007-12-27

Similar Documents

Publication Publication Date Title
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
DE69325998D1 (de) Verwendung von beta-hydroxy-beta-methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
ATE405277T1 (de) Substitutions-infusionflüssigkeit und zitratanticoagulation
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
EP1393734A4 (en) DRUG AGAINST DARMER DISEASES
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
FR2836336B1 (fr) Utilisation dans un traitement cosmetique d&#39;une fraction phenolique riche en dihydrochalcones
TR199701121T1 (xx) Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
NO308856B1 (no) Dermatansulfater og salter av disse
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0012661A (pt) Métodos de tratamento e métodos de triagem de drogas
BR9713514A (pt) Novo uso de creatina
EP0373771A3 (en) New pharmaceutical uses for cystatins
EP0880967A3 (de) Nephroprotektive Arzneimittel
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: PORTANTO, EM FACE AO EXPOSTO ACIMA, E DE ACORDO COM O ARTIGO 37, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO, TENDO POR BASE OS ARTIGOS 8O, 13, 24 E 25 DA LEI 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]